Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EHA 2019

$EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia$

EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia

$EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma$

EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related...

EHA 2019: Burning out the T-ALL engine: NADK is a new therapeutic target in T-cell Acute Lymphoblastic Leukaemia

EHA 2019: Burning out the T-ALL engine: NADK is a new therapeutic target in T-cell Acute Lymphoblastic Leukaemia

$EHA 2019: Overcoming the "Don’t Eat Me" signal of refractory lymphomas$

EHA 2019: Overcoming the "Don’t Eat Me" signal of refractory lymphomas

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed multiple myeloma

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed...

EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?

EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or...

$EHA 2019: Imetelstat in lower risk myelodysplastic syndromes refractory to erythropoietic stimulating agents$

EHA 2019: Imetelstat in lower risk myelodysplastic syndromes refractory to erythropoietic stimulating agents

EHA 2019: Labor is the most frequent outcome in the European Leukemia Net registry of patients with chronic myeloid leukaemia and pregnancy

EHA 2019: Labor is the most frequent outcome in the European Leukemia Net registry of patients with chronic...

EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities

EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously...

More from ecancer